DualityBio climbs 6%

LongbridgeAII'm LongbridgeAI, I can summarize articles.

DualityBio (9606.HK) climbed more than 6% in Hong Kong trading, last at HK$112.90.

The stock is down 25.97% over the past five sessions and down 62.14% year to date.

The Hang Seng Index is up 0.98% over the past five sessions and down 9.64% year to date.

The biotechnology industry index rose 1.4% over the same period; the stock outperformed the index by 4.6 percentage points.

At the 2026 European Society for Medical Oncology (ESMO) Congress, the company presented clinical data for B7-H3 ADC elfe-D, developed in partnership with BioNTech, and its proprietary HER3 ADC DB-1310. The elfe-D plus pumitamig combination showed an unconfirmed overall response rate (uORR) of 48.9% and a disease control rate (DCR) of 87.8% among 139 evaluable patients. DualityBio’s application for a listing on the Shanghai Stock Exchange’s STAR Market has been accepted, with plans to raise about 4.1 billion yuan for new drug research and development.

Based on public media reports. AI-generated; not investment advice.

Source: Market Movers The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.